Riemke Van Dijkhuizen Radersma

This inventor holds 6 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignee: Genmab A+s. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Riemke Van Dijkhuizen Radersma. Retrieved from https://idiyas.com/inventor/riemke-van-dijkhuizen-radersma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 23(Granted Patents)

Location History:

Zeist, NL (2019 - 2020)
Utrecht, NL (2020)

Company Filing History:

6 out of 107

Genmab A+s

patents

Years Active: 2019-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12589150 - ANTIBODIES BINDING AXL (2026-03-31),

2. 10765743 - Antibodies binding AXL (2020-09-08),

3. 10544220 - Bispecific antibodies against CD3 and CD20 (2020-01-28),

4. 10512688 - Antibodies binding AXL (2019-12-24),

5. 10500276 - Antibodies binding AXL (2019-12-10),

6. 10201607 - Antibodies binding AXL (2019-02-12),

Title: Riemke Van Dijkhuizen Radersma: Innovator in Cancer Treatment

Introduction

Riemke Van Dijkhuizen Radersma is a notable inventor based in Zeist, Netherlands. He has made significant contributions to the field of cancer treatment through his innovative work in antibody development. With a total of five patents to his name, he is recognized for his advancements in targeted therapies.

Latest Patents

Riemke's latest patents include groundbreaking inventions such as anti-AXL antibodies. This invention relates to antibodies that bind to AXL, along with immunoconjugates, compositions, and methods for treating cancer using these antibodies. Another significant patent involves bispecific antibodies against CD3 and CD20. These bispecific antibodies are designed for specific targeting and T cell-mediated killing of cells that express CD20, which is crucial in treating certain diseases.

Career Highlights

Riemke is currently associated with Genmab AS, a leading biotechnology company focused on developing differentiated antibody therapeutics for the treatment of cancer. His work at Genmab has positioned him as a key player in the advancement of innovative cancer therapies.

Collaborations

Riemke collaborates with talented professionals in his field, including Esther Breij and David Satijn. Their combined expertise contributes to the success of their projects and the development of new therapeutic solutions.

Conclusion

Riemke Van Dijkhuizen Radersma is a prominent inventor whose work in antibody development is paving the way for innovative cancer treatments. His contributions are vital in the ongoing fight against cancer, showcasing the importance of research and innovation in medicine.

Profile summary based on public USPTO records.